The sharp decline in IINN shares following the patent approval announcement suggests a strong market reaction, likely due to profit-taking. Given the innovative nature of the VORTX technology and its potential to disrupt traditional blood oxygenation methods, this news is highly relevant and important to investors. However, the immediate negative impact on the stock price indicates a short-term bearish outlook, despite the long-term potential benefits of the technology.